Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes.
The effect of dansylcadaverine, amantadine, and rimantadine on phagocytosis, release of PAF-acether, phospholipid methylation, and phosphatidylcholine formation by the cholinephosphotransferase pathway was assessed in human peripheral polymorphonuclear leukocytes. All of the drugs induced a dose-dependent and reversible inhibition in the uptake of complement-coated zymosan particles as well as a reduction in the release of PAF-acether. Simultaneously, a marked reduction in the formation of phosphatidylcholine was observed. This was also dose-dependent and reversible, and showed this order of potency: dansylcadaverine greater than rimantadine greater than amantadine. Dansylcadaverine reduced phospholipid methylation to a lesser extent than the cholinephosphotransferase pathway. These data show that drugs that block receptor-mediated endocytosis inhibit the response of the human polymorphonuclear cell and suggest that this action may be mediated by their actions on phospholipid metabolism.
D000218:Adamantane / Q000031:analogs & derivatives*; D000547:Amantadine / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002103:Cadaverine / Q000031:analogs & derivatives* / Q000494:pharmacology; D003959:Diamines; D006801:Humans; D009504:Neutrophils / Q000276:immunology* / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects*; D010713:Phosphatidylcholines / Q000096:biosynthesis*; D010972:Platelet Activating Factor / Q000096:biosynthesis*; D012299:Rimantadine / Q000494:pharmacology*
D000970:Antineoplastic Agents; D003959:Diamines; D010713:Phosphatidylcholines; D010972:Platelet Activating Factor; D012299:Rimantadine; D000547:Amantadine; C008542:monodansylcadaverine; D002103:Cadaverine; D000218:Adamantane